From the Journals

Consider hydroxychloroquine in treating pediatric alopecia areata


 

FROM PEDIATRIC DERMATOLOGY

Hydroxychloroquine could be beneficial as a treatment option for children with alopecia areata (AA), according to Duri Yun, MD, of the University of Chicago Medicine, and associates.

In a retrospective review published in Pediatric Dermatology, nine children aged 6-16 years with AA and diverse ethnicities were treated with hydroxychloroquine between July 1, 2013, and July 1, 2015; all had failed multiple previous treatment modalities. In patient 1, hydroxychloroquine therapy was initiated, fine hair regrowth occurred after 5 months of therapy and was maintained, with dosage tapered to 200 mg once daily after 1 year. After 2 years of therapy, hair had nearly completely regrown. Similar results occurred in patient 2, who had nearly complete hair loss within 2 weeks of initiating hydroxychloroquine. Steady regrowth continued to near-complete regrowth after 1 year of treatment, when dosage was tapered to 200 mg once daily.

Abbassyma/Wikimedia Commons/Public Domain
Patient 6, who had moderate AA, had nearly 50% hair regrowth by 6 months of treatment. Patient 8, who had alopecia totalis, recovered 78% of hair while on therapy and has maintained approximately 50% of his hair regrowth while off therapy. In addition, patient 9, who also had alopecia totalis, experienced 87% hair regrowth on hydroxychloroquine therapy.

Four patients (44%) had no evidence of regrowth after 4-6 months of hydroxychloroquine therapy so they discontinued therapy. The most common adverse events while taking hydroxychloroquine were abdominal pain in two patients (22%) and headache in two patients (22%).

“In the context of children with severe AA failing multiple first-line therapies, our findings suggest that there may be a subgroup that benefits from therapy with hydroxychloroquine,” the researchers concluded. “Determining which factors might predict response to various therapies will come from combined efforts to conduct well-controlled clinical trials of treatments for AA.”

SOURCE: Yun D et al., Pediatr Dermatol. 2018 Mar 25. doi: 10.1111/pde.13451.

Recommended Reading

Cost, coverage concerns cited as barriers to acne medication adherence
MDedge Dermatology
Clinical pattern may help distinguish pediatric NMN from subungal melanoma
MDedge Dermatology
Study using U.K. data quantifies infection risk associated with psoriasis
MDedge Dermatology
Pilot study: Topical anticholinergic improved axillary hyperhidrosis in teens, young adults
MDedge Dermatology
Alopecia areata has female predominance, more severe types common in boys
MDedge Dermatology
National Rosacea Society designates April as “Rosacea Awareness Month”
MDedge Dermatology
Pediatric Dermatology Consult - March 2018
MDedge Dermatology
MDedge Daily News: Does more marijuana mean fewer opioids?
MDedge Dermatology
Posttransplant skin conditions vary widely by ethnicity
MDedge Dermatology
From weekend warriors to pros, athletes are plagued by skin disorders
MDedge Dermatology